Abivax announces German regulatory approval of ABX464 Covid-19 Phase 2b/3 COVID-19 clinical trial
Abivax said Monday that the German regulatory authority for drugs and medical products, BfArM (Bundesinstitut für Arnzeimittel und Medizinprodukte), has approved its Phase 2b/3 study of ABX464 in COVID-19 patients.